Adjuvant therapy for high-risk renal cell carcinoma patients

被引：26

作者：

Kunkle D.A. ^{[1
]}

Haas N.B. ^{[1
]}

Uzzo R.G. ^{[1
]}

机构：

[1] Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111

来源：

Current Urology Reports | 2007年 / 8卷 / 1期

基金：

英国医学研究理事会;

关键词：

Renal Cell Carcinoma; Clin Oncol; Sorafenib; Sunitinib; Metastatic Renal Cell Carcinoma;

D O I：

10.1007/s11934-007-0017-5

中图分类号：

学科分类号：

摘要：

For most cases of renal cell carcinoma (RCC), the standard of care is surgical resection as monotherapy or as part of a multimodal approach. In patients with early localized disease, radical nephrectomy is associated with a favorable prognosis, whereas patients with advanced disease are rarely cured. A significant number of patients undergoing surgery for localized RCC experience recurrence, suggesting that there are some individuals in whom surgical excision is necessary but insufficient. In these patients, the development of effective adjuvant strategies is imperative. In this article, we review the prognostic variables and comprehensive staging algorithms for identifying patients at high risk for disease recurrence. Additionally, we review data from completed adjuvant RCC trials and highlight relevant ongoing trials. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：19 / 30

页数：11

共 63 条

[41]

Bui M.H., Visapaa H., Seligson D., Et al., Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma, J Urol, 171, pp. 2461-2466, (2004)

[42]

Li E., Bestor T.H., Jaenisch R., Targeted mutation of the DNA methyltransferase gene results in embryonic lethality, Cell, 69, pp. 915-926, (1992)

[43]

Jones P.A., Baylin S.B., The fundamental role of epigenetic events in cancer, Nat Rev Genet, 3, pp. 415-428, (2002)

[44]

Patard J.J., Kim H.L., Lam J.S., Et al., Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study, J Clin Oncol, 22, pp. 3316-3322, (2004)

[45]

Leibovich B.C., Han K., Bui M.H.T., Et al., Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma, Cancer, 98, pp. 2566-2575, (2003)

[46]

Motzer R.J., Bacik J., Murphy B.A., et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, pp. 289-296, (2002)

[47]

Ficarra V., Martignoni G., Lohse C., Et al., External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma, J Urol, 175, pp. 1235-1239, (2006)

[48]

Kjaer M., Frederiksen P.L., Engelholm S.A., Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group, Int J Radiat Oncol Biol Phys, 13, pp. 665-672, (1987)

[49]

Kjaer M., Iversen P., Hvidt V., Et al., A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group, Scand J Urol Nephrol, 21, pp. 285-289, (1987)

[50]

Pizzocaro G., Piva L., Di Fronzo G., Et al., Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study, J Urol, 138, pp. 1379-1381, (1987)

← 1 2 3 4 5 6 7 →